Selected research
Industry Research
AI Drug Target Discovery Service Industry Research Report 2026
Market perspective
The global AI Drug Target Discovery Service market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the AI Drug Target Discovery Service market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the AI Drug Target Discovery Service market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the AI Drug Target Discovery Service market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of AI Drug Target Discovery Service include Exscientia, Atomwise, Benevolent AI, Insitro, Xaira Therapeutics, Tempus AI, AbCellera, Recursion and Iktos, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global AI Drug Target Discovery Service market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to AI Drug Target Discovery Service.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
AI Drug Target Discovery Service Market by Company
Exscientia
Atomwise
Benevolent AI
Insitro
Xaira Therapeutics
Tempus AI
AbCellera
Recursion
Iktos
Genialis
Anima Biotech
BPGbio
Cradle
Isomorphic Labs
Generate Biomedicines
Latent Labs
Relay Therapeutics
Model Medicines
Nimbus Therapeutics
Schrödinger
XtalPi
Insilico Medicine
Drug Farm
BioMap
AI Drug Target Discovery Service Segment by Type
Target Identification Based on Omics Data and Biological Networks
Target Mining Based on Literature and Knowledge Graphs
Target Prediction Based on Structural Bioinformatics
Target Discovery Based on Phenotypic Screening and Virtual Patients
AI Drug Target Discovery Service Segment by Application
Pharmaceutical Company
CRO and Universities
Others
AI Drug Target Discovery Service Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global AI Drug Target Discovery Service market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of AI Drug Target Discovery Service and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of AI Drug Target Discovery Service.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of AI Drug Target Discovery Service companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Target Identification Based on Omics Data and Biological Networks
- Target Mining Based on Literature and Knowledge Graphs
- Target Prediction Based on Structural Bioinformatics
- Target Discovery Based on Phenotypic Screening and Virtual Patients
Applications
- Pharmaceutical Company
- CRO and Universities
- Others
Companies covered
- Exscientia
- Atomwise
- Benevolent AI
- Insitro
- Xaira Therapeutics
- Tempus AI
- AbCellera
- Recursion
- Iktos
- Genialis
- Anima Biotech
- BPGbio
- Cradle
- Isomorphic Labs
- Generate Biomedicines
- Latent Labs
- Relay Therapeutics
- Model Medicines
- Nimbus Therapeutics
- Schrödinger
- XtalPi
- Insilico Medicine
- Drug Farm
- BioMap
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 AI Drug Target Discovery Service by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Target Identification Based on Omics Data and Biological Networks
- 2.2.3 Target Mining Based on Literature and Knowledge Graphs
- 2.2.4 Target Prediction Based on Structural Bioinformatics
- 2.2.5 Target Discovery Based on Phenotypic Screening and Virtual Patients
- 2.3 AI Drug Target Discovery Service by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Pharmaceutical Company
- 2.3.3 CRO and Universities
- 2.3.4 Others
- 2.4 Assumptions and Limitations
3 AI Drug Target Discovery Service Breakdown Data by Type
- 3.1 Global AI Drug Target Discovery Service Historic Market Size by Type (2021-2026)
- 3.2 Global AI Drug Target Discovery Service Forecasted Market Size by Type (2027-2032)
4 AI Drug Target Discovery Service Breakdown Data by Application
- 4.1 Global AI Drug Target Discovery Service Historic Market Size by Application (2021-2026)
- 4.2 Global AI Drug Target Discovery Service Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global AI Drug Target Discovery Service Market Perspective (2021-2032)
- 5.2 Global AI Drug Target Discovery Service Growth Trends by Region
- 5.2.1 Global AI Drug Target Discovery Service Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 AI Drug Target Discovery Service Historic Market Size by Region (2021-2026)
- 5.2.3 AI Drug Target Discovery Service Forecasted Market Size by Region (2027-2032)
- 5.3 AI Drug Target Discovery Service Market Dynamics
- 5.3.1 AI Drug Target Discovery Service Industry Trends
- 5.3.2 AI Drug Target Discovery Service Market Drivers
- 5.3.3 AI Drug Target Discovery Service Market Challenges
- 5.3.4 AI Drug Target Discovery Service Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top AI Drug Target Discovery Service Players by Revenue
- 6.1.1 Global Top AI Drug Target Discovery Service Players by Revenue (2021-2026)
- 6.1.2 Global AI Drug Target Discovery Service Revenue Market Share by Players (2021-2026)
- 6.2 Global AI Drug Target Discovery Service Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of AI Drug Target Discovery Service Head Office and Area Served
- 6.4 Global AI Drug Target Discovery Service Players, Product Type & Application
- 6.5 Global AI Drug Target Discovery Service Manufacturers Established Date
- 6.6 Global AI Drug Target Discovery Service Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America AI Drug Target Discovery Service Market Size (2021-2032)
- 7.2 North America AI Drug Target Discovery Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America AI Drug Target Discovery Service Market Size by Country (2021-2026)
- 7.4 North America AI Drug Target Discovery Service Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe AI Drug Target Discovery Service Market Size (2021-2032)
- 8.2 Europe AI Drug Target Discovery Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe AI Drug Target Discovery Service Market Size by Country (2021-2026)
- 8.4 Europe AI Drug Target Discovery Service Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific AI Drug Target Discovery Service Market Size (2021-2032)
- 9.2 Asia-Pacific AI Drug Target Discovery Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific AI Drug Target Discovery Service Market Size by Country (2021-2026)
- 9.4 Asia-Pacific AI Drug Target Discovery Service Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America AI Drug Target Discovery Service Market Size (2021-2032)
- 10.2 South America AI Drug Target Discovery Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America AI Drug Target Discovery Service Market Size by Country (2021-2026)
- 10.4 South America AI Drug Target Discovery Service Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa AI Drug Target Discovery Service Market Size (2021-2032)
- 11.2 Middle East & Africa AI Drug Target Discovery Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa AI Drug Target Discovery Service Market Size by Country (2021-2026)
- 11.4 Middle East & Africa AI Drug Target Discovery Service Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Exscientia
- 12.1.1 Exscientia Company Information
- 12.1.2 Exscientia Business Overview
- 12.1.3 Exscientia Revenue in AI Drug Target Discovery Service Business (2021-2026)
- 12.1.4 Exscientia AI Drug Target Discovery Service Product Portfolio
- 12.1.5 Exscientia Recent Developments
- 12.2 Atomwise
- 12.2.1 Atomwise Company Information
- 12.2.2 Atomwise Business Overview
- 12.2.3 Atomwise Revenue in AI Drug Target Discovery Service Business (2021-2026)
- 12.2.4 Atomwise AI Drug Target Discovery Service Product Portfolio
- 12.2.5 Atomwise Recent Developments
- 12.3 Benevolent AI
- 12.3.1 Benevolent AI Company Information
- 12.3.2 Benevolent AI Business Overview
- 12.3.3 Benevolent AI Revenue in AI Drug Target Discovery Service Business (2021-2026)
- 12.3.4 Benevolent AI AI Drug Target Discovery Service Product Portfolio
- 12.3.5 Benevolent AI Recent Developments
- 12.4 Insitro
- 12.4.1 Insitro Company Information
- 12.4.2 Insitro Business Overview
- 12.4.3 Insitro Revenue in AI Drug Target Discovery Service Business (2021-2026)
- 12.4.4 Insitro AI Drug Target Discovery Service Product Portfolio
- 12.4.5 Insitro Recent Developments
- 12.5 Xaira Therapeutics
- 12.5.1 Xaira Therapeutics Company Information
- 12.5.2 Xaira Therapeutics Business Overview
- 12.5.3 Xaira Therapeutics Revenue in AI Drug Target Discovery Service Business (2021-2026)
- 12.5.4 Xaira Therapeutics AI Drug Target Discovery Service Product Portfolio
- 12.5.5 Xaira Therapeutics Recent Developments
- 12.6 Tempus AI
- 12.6.1 Tempus AI Company Information
- 12.6.2 Tempus AI Business Overview
- 12.6.3 Tempus AI Revenue in AI Drug Target Discovery Service Business (2021-2026)
- 12.6.4 Tempus AI AI Drug Target Discovery Service Product Portfolio
- 12.6.5 Tempus AI Recent Developments
- 12.7 AbCellera
- 12.7.1 AbCellera Company Information
- 12.7.2 AbCellera Business Overview
- 12.7.3 AbCellera Revenue in AI Drug Target Discovery Service Business (2021-2026)
- 12.7.4 AbCellera AI Drug Target Discovery Service Product Portfolio
- 12.7.5 AbCellera Recent Developments
- 12.8 Recursion
- 12.8.1 Recursion Company Information
- 12.8.2 Recursion Business Overview
- 12.8.3 Recursion Revenue in AI Drug Target Discovery Service Business (2021-2026)
- 12.8.4 Recursion AI Drug Target Discovery Service Product Portfolio
- 12.8.5 Recursion Recent Developments
- 12.9 Iktos
- 12.9.1 Iktos Company Information
- 12.9.2 Iktos Business Overview
- 12.9.3 Iktos Revenue in AI Drug Target Discovery Service Business (2021-2026)
- 12.9.4 Iktos AI Drug Target Discovery Service Product Portfolio
- 12.9.5 Iktos Recent Developments
- 12.10 Genialis
- 12.10.1 Genialis Company Information
- 12.10.2 Genialis Business Overview
- 12.10.3 Genialis Revenue in AI Drug Target Discovery Service Business (2021-2026)
- 12.10.4 Genialis AI Drug Target Discovery Service Product Portfolio
- 12.10.5 Genialis Recent Developments
- 12.11 Anima Biotech
- 12.11.1 Anima Biotech Company Information
- 12.11.2 Anima Biotech Business Overview
- 12.11.3 Anima Biotech Revenue in AI Drug Target Discovery Service Business (2021-2026)
- 12.11.4 Anima Biotech AI Drug Target Discovery Service Product Portfolio
- 12.11.5 Anima Biotech Recent Developments
- 12.12 BPGbio
- 12.12.1 BPGbio Company Information
- 12.12.2 BPGbio Business Overview
- 12.12.3 BPGbio Revenue in AI Drug Target Discovery Service Business (2021-2026)
- 12.12.4 BPGbio AI Drug Target Discovery Service Product Portfolio
- 12.12.5 BPGbio Recent Developments
- 12.13 Cradle
- 12.13.1 Cradle Company Information
- 12.13.2 Cradle Business Overview
- 12.13.3 Cradle Revenue in AI Drug Target Discovery Service Business (2021-2026)
- 12.13.4 Cradle AI Drug Target Discovery Service Product Portfolio
- 12.13.5 Cradle Recent Developments
- 12.14 Isomorphic Labs
- 12.14.1 Isomorphic Labs Company Information
- 12.14.2 Isomorphic Labs Business Overview
- 12.14.3 Isomorphic Labs Revenue in AI Drug Target Discovery Service Business (2021-2026)
- 12.14.4 Isomorphic Labs AI Drug Target Discovery Service Product Portfolio
- 12.14.5 Isomorphic Labs Recent Developments
- 12.15 Generate Biomedicines
- 12.15.1 Generate Biomedicines Company Information
- 12.15.2 Generate Biomedicines Business Overview
- 12.15.3 Generate Biomedicines Revenue in AI Drug Target Discovery Service Business (2021-2026)
- 12.15.4 Generate Biomedicines AI Drug Target Discovery Service Product Portfolio
- 12.15.5 Generate Biomedicines Recent Developments
- 12.16 Latent Labs
- 12.16.1 Latent Labs Company Information
- 12.16.2 Latent Labs Business Overview
- 12.16.3 Latent Labs Revenue in AI Drug Target Discovery Service Business (2021-2026)
- 12.16.4 Latent Labs AI Drug Target Discovery Service Product Portfolio
- 12.16.5 Latent Labs Recent Developments
- 12.17 Relay Therapeutics
- 12.17.1 Relay Therapeutics Company Information
- 12.17.2 Relay Therapeutics Business Overview
- 12.17.3 Relay Therapeutics Revenue in AI Drug Target Discovery Service Business (2021-2026)
- 12.17.4 Relay Therapeutics AI Drug Target Discovery Service Product Portfolio
- 12.17.5 Relay Therapeutics Recent Developments
- 12.18 Model Medicines
- 12.18.1 Model Medicines Company Information
- 12.18.2 Model Medicines Business Overview
- 12.18.3 Model Medicines Revenue in AI Drug Target Discovery Service Business (2021-2026)
- 12.18.4 Model Medicines AI Drug Target Discovery Service Product Portfolio
- 12.18.5 Model Medicines Recent Developments
- 12.19 Nimbus Therapeutics
- 12.19.1 Nimbus Therapeutics Company Information
- 12.19.2 Nimbus Therapeutics Business Overview
- 12.19.3 Nimbus Therapeutics Revenue in AI Drug Target Discovery Service Business (2021-2026)
- 12.19.4 Nimbus Therapeutics AI Drug Target Discovery Service Product Portfolio
- 12.19.5 Nimbus Therapeutics Recent Developments
- 12.20 Schrödinger
- 12.20.1 Schrödinger Company Information
- 12.20.2 Schrödinger Business Overview
- 12.20.3 Schrödinger Revenue in AI Drug Target Discovery Service Business (2021-2026)
- 12.20.4 Schrödinger AI Drug Target Discovery Service Product Portfolio
- 12.20.5 Schrödinger Recent Developments
- 12.21 XtalPi
- 12.21.1 XtalPi Company Information
- 12.21.2 XtalPi Business Overview
- 12.21.3 XtalPi Revenue in AI Drug Target Discovery Service Business (2021-2026)
- 12.21.4 XtalPi AI Drug Target Discovery Service Product Portfolio
- 12.21.5 XtalPi Recent Developments
- 12.22 Insilico Medicine
- 12.22.1 Insilico Medicine Company Information
- 12.22.2 Insilico Medicine Business Overview
- 12.22.3 Insilico Medicine Revenue in AI Drug Target Discovery Service Business (2021-2026)
- 12.22.4 Insilico Medicine AI Drug Target Discovery Service Product Portfolio
- 12.22.5 Insilico Medicine Recent Developments
- 12.23 Drug Farm
- 12.23.1 Drug Farm Company Information
- 12.23.2 Drug Farm Business Overview
- 12.23.3 Drug Farm Revenue in AI Drug Target Discovery Service Business (2021-2026)
- 12.23.4 Drug Farm AI Drug Target Discovery Service Product Portfolio
- 12.23.5 Drug Farm Recent Developments
- 12.24 BioMap
- 12.24.1 BioMap Company Information
- 12.24.2 BioMap Business Overview
- 12.24.3 BioMap Revenue in AI Drug Target Discovery Service Business (2021-2026)
- 12.24.4 BioMap AI Drug Target Discovery Service Product Portfolio
- 12.24.5 BioMap Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst